依洛尤单抗对脂蛋白(a)颗粒动力学影响的对照研究
研究纳入63名血浆载脂蛋白(a)浓度>5 nmol/L的健康男性,参与8周析因试验,探讨依洛尤单抗降低脂蛋白(a)的机制。结果显示,依洛尤单抗单药治疗通过减少脂蛋白(a)颗粒生成降低血浆池大小,而与阿托伐他汀联用时则通过加速分解代谢降低池大小。
要点
- 依洛尤单抗单药降低脂蛋白(a)池大小36%,源于生成减少36%。
- 依洛尤单抗联用阿托伐他汀时,脂蛋白(a)分解代谢增加59%,生成无变化。
- 脂蛋白(a)-apo(a)与脂蛋白(a)-apoB分解代谢变化高度相关(r=0.966)。
核心结论
- 依洛尤单抗单药通过减少脂蛋白(a)颗粒生成降低血浆池大小,与阿托伐他汀联用时通过加速分解代谢降低池大小。
研究设计与样本
- 63名健康男性,血浆载脂蛋白(a)浓度>5 nmol/L,参与8周析因试验,接受依洛尤单抗420 mg每2周和阿托伐他汀80 mg每日治疗。
- 采用静脉D3-亮氨酸、质谱和区室模型研究脂蛋白(a)-apo(a)动力学,其中16名受试者另测脂蛋白(a)-apoB动力学。
主要发现
- 依洛尤单抗(而非阿托伐他汀)显著降低脂蛋白(a)-apo(a)血浆池大小(-36%,P<0.001)。
- 依洛尤单抗单药显著降低脂蛋白(a)-apo(a)生成(-36%,P<0.001)。
- 依洛尤单抗联用阿托伐他汀显著增加脂蛋白(a)-apo(a)分解代谢(+59%,P<0.001),对生成无影响。
- 16名受试者中,脂蛋白(a)-apo(a)与脂蛋白(a)-apoB分解代谢变化高度相关(r=0.966,P<0.001)。
临床怎么用
- 依洛尤单抗可降低脂蛋白(a)水平,单药与联用他汀的机制不同,为他汀基础上管理脂蛋白(a)升高提供依据。
局限性
- 研究人群为健康男性,非心血管疾病患者,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Lipoprotein(a) [Lp(a)], a low-density lipoprotein (LDL) particle covalently bound to apolipoprotein(a) [apo(a)], is a potentially potent heritable risk factor for cardiovascular disease. We investigated the mechanism whereby evolocumab, a monoclonal antibody against proprotein convertase subtilisin-kexin type 9 (PCSK9), lowers Lp(a). METHODS AND RESULTS: We studied the kinetics of Lp(a) particles in 63 healthy men, with plasma apo(a) concentration >5 nmol/L, participating in an 8-week factorial trial of the effects of evolocumab (420 mg every 2 weeks) and atorvastatin (80 mg daily) on lipoprotein metabolism. Lipoprotein(a)-apo(a) kinetics were studied using intravenous D3-leucine administration, mass spectrometry, and compartmental modelling; Lp(a)-apoB kinetics were also determined in 16 subjects randomly selected from the treatment groups. Evolocumab, but not atorvastatin, significantly decreased the plasma pool size of Lp(a)-apo(a) (-36%, P < 0.001 for main effect). As monotherapy, evolocumab significantly decreased the production of Lp(a)-apo(a) (-36%, P < 0.001). In contrast, in combination with atorvastatin, evolocumab significantly increased the fractional catabolism of Lp(a)-apo(a) (+59%, P < 0.001), but had no effect on the production of Lp(a)-apo(a). There was a highly significant association between the changes in the fractional catabolism of Lp(a)-apo(a) and Lp(a)-apoB in the substudy of 16 subjects (r = 0.966, P < 0.001). CONCLUSIONS: Evolocumab monotherapy lowered the plasma Lp(a) pool size by decreasing the production of Lp(a) particles. In combination with atorvastatin, evolocumab lowered the plasma Lp(a) pool size by accelerating the catabolism of Lp(a) particles. This dual mechanism may relate to an effect of PCSK9 inhibition on Lp(a)-apo(a) production and to marked up-regulation of LDL receptor activity on Lp(a) holoparticle clearance. CLINICAL TRIAL REGISTRATION INFORMATION: NCT02189837.
引用
- Watts GF, Chan DC, Somaratne R, et al. Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics. Eur Heart J. 2018. PMID: 29566128. doi:10.1093/eurheartj/ehy122
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。